Clostridium tetani toxoid antigen (formaldehyde inactivated)

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Clostridium tetani toxoid antigen (formaldehyde inactivated)
Accession Number
DB10583
Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Inactivated / Toxoid
Description

Clostridium tetani toxoid antigen (formaldehyde inactivated) is a vaccine for intramuscular injection. It is used for active immunization of children 7 years of age or older, and adults, for prevention of tetanus. The toxoid in the Clostridium tetani culture is grown and detoxified followed by purification via ammonium sulfate filtration and precipation.

Synonyms
  • Tetanus toxoid
  • Tetanus toxoid adsorbed
  • tetanus toxoid vaccine, inactivated
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Tetanus Toxoid AdsorbedInjection, suspension5 [Lf]/.5mLIntramuscularSanofi Pasteur Limited2005-09-232017-04-25Us
Tetanus Toxoid AdsorbedSuspension5 lfIntramuscularId Biomedical Corporation, Quebec1991-12-312005-08-03Canada
Tetanus Toxoid AdsorbedInjection, suspension5 [Lf]/.5mLIntramuscularSanofi Pasteur Limited2005-09-232017-04-25Us
Tetanus Toxoid Adsorbed InjLiquid5 lfIntramuscularAventis Pasteur Limited1980-12-312006-07-17Canada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Adacel TDaPClostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (5 ug/.5mL) + Bordetella pertussis fimbriae 2/3 antigen (5 ug/.5mL) + Bordetella pertussis pertactin antigen (3 ug/.5mL) + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (2.5 ug/.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2 [Lf]/.5mL)Injection, suspensionIntramuscularSanofi Pasteur Limited2005-06-10Not applicableUs
Adacel TDaP TDaPClostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (5 ug/.5mL) + Bordetella pertussis fimbriae 2/3 antigen (5 ug/.5mL) + Bordetella pertussis pertactin antigen (3 ug/.5mL) + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (2.5 ug/.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2 [Lf]/.5mL)Injection, suspensionIntramuscularRemedy Repack2015-10-192016-03-31Us
BoostrixClostridium tetani toxoid antigen (formaldehyde inactivated) (5 [iU]/.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (8 ug/.5mL) + Bordetella pertussis pertactin antigen (formaldehyde inactivated) (2.5 ug/.5mL) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (8 ug/.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2.5 [iU]/.5mL)SuspensionIntramuscularA S Medication Solutions2009-07-242017-06-20Us
BoostrixClostridium tetani toxoid antigen (formaldehyde inactivated) (5 [iU]/.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (8 ug/.5mL) + Bordetella pertussis pertactin antigen (formaldehyde inactivated) (2.5 ug/.5mL) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (8 ug/.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2.5 [iU]/.5mL)SuspensionIntramuscularA S Medication Solutions2009-07-24Not applicableUs
BoostrixClostridium tetani toxoid antigen (formaldehyde inactivated) (5 [iU]/.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (8 ug/.5mL) + Bordetella pertussis pertactin antigen (formaldehyde inactivated) (2.5 ug/.5mL) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (8 ug/.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2.5 [iU]/.5mL)SuspensionIntramuscularGlaxo Smith Kline Biologicals Sa2009-07-24Not applicableUs
CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED), CORYNEBACTERIUM DIPHTHERIAE TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED), BORDETELLA PERTUSSIS TOXOID ANTIGEN (GLUTARALDEHYDE INACTIVATED), BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED), BORDETELLA PERTUSSIS PERTACTIN ANTIGEN, and BORDETELLA PERTUSSIS FIMBRIAE 2/3 ANTIGENClostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (5 ug/.5mL) + Bordetella pertussis fimbriae 2/3 antigen (5 ug/.5mL) + Bordetella pertussis pertactin antigen (3 ug/.5mL) + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (2.5 ug/.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2 [Lf]/.5mL)Injection, suspensionIntramuscularA S Medication Solutions2005-06-102017-06-20Us
D2t5 Diphtheria and Tetanus Toxoid AdsorbedClostridium tetani toxoid antigen (formaldehyde inactivated) (5 lf) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2 lf)SuspensionIntramuscularIaf Biovac Inc.1998-06-291999-01-08Canada
DaptacelClostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (5 ug/.5mL) + Bordetella pertussis fimbriae 2/3 antigen (5 ug/.5mL) + Bordetella pertussis pertactin antigen (3 ug/.5mL) + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (10 ug/.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (15 [Lf]/.5mL)Injection, suspensionIntramuscularSanofi Pasteur Limited2002-05-14Not applicableUs
DecavacClostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2 [Lf]/.5mL)SuspensionIntramuscularSanofi Pasteur Limited2004-03-242016-10-13Us
Diphtheria and Tetanus Toxoids AdsorbedClostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (25 [Lf]/.5mL)Injection, suspensionIntramuscularSanofi Pasteur Limited2010-03-29Not applicableUs
Categories
UNII
K3W1N8YP13
CAS number
Not Available

Pharmacology

Indication
Not Available
Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Experimental, Illicit
2-MethoxyethanolThe risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Experimental
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Experimental, Illicit
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
AbetimusThe risk or severity of adverse effects can be increased when Abetimus is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Investigational
AbituzumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Abituzumab.Investigational
ActeosideThe risk or severity of adverse effects can be increased when Acteoside is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Investigational
AdalimumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Adalimumab.Approved
AdecatumumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Adecatumumab.Investigational
AdefovirThe risk or severity of adverse effects can be increased when Adefovir is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Investigational
AducanumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Aducanumab.Investigational
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Investigational
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
AldesleukinThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Aldesleukin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Experimental, Investigational
AlefaceptThe risk or severity of adverse effects can be increased when Alefacept is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational, Withdrawn
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
AlicaforsenThe risk or severity of adverse effects can be increased when Alicaforsen is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Investigational
AlirocumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Alirocumab.Approved
AltretamineThe risk or severity of adverse effects can be increased when Altretamine is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
AmatuximabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Amatuximab.Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
AMG 108The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with AMG 108.Investigational
AmsacrineThe risk or severity of adverse effects can be increased when Amsacrine is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
AnakinraThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Anakinra.Approved
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Investigational
AnifrolumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Anifrolumab.Investigational
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
ApolizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Apolizumab.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
AscrinvacumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ascrinvacumab.Investigational
Asfotase AlfaThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Asfotase Alfa.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Investigational
AtezolizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Atezolizumab.Approved, Investigational
AVE9633The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with AVE9633.Investigational
AvelumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Avelumab.Approved, Investigational
AzacitidineThe risk or severity of adverse effects can be increased when Azacitidine is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
AzathioprineThe risk or severity of adverse effects can be increased when Azathioprine is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
BapineuzumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bapineuzumab.Investigational
BasiliximabThe risk or severity of adverse effects can be increased when Basiliximab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
BavituximabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bavituximab.Investigational
Beclomethasone dipropionateThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Beclomethasone dipropionate.Approved, Investigational
BectumomabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bectumomab.Investigational
BegelomabThe risk or severity of adverse effects can be increased when Begelomab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Experimental, Investigational
BelataceptThe risk or severity of adverse effects can be increased when Belatacept is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
BelimumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Belimumab.Approved
BenznidazoleThe risk or severity of adverse effects can be increased when Benznidazole is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
BesilesomabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Besilesomab.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Vet Approved
BevacizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bevacizumab.Approved, Investigational
BIIB015The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with BIIB015.Investigational
BimagrumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bimagrumab.Investigational
BivatuzumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bivatuzumab.Investigational
BleomycinThe risk or severity of adverse effects can be increased when Bleomycin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
BlinatumomabThe risk or severity of adverse effects can be increased when Blinatumomab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
BlosozumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Blosozumab.Investigational
BococizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bococizumab.Investigational
Brentuximab vedotinThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
BriakinumabThe risk or severity of adverse effects can be increased when Briakinumab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Investigational
BrodalumabThe risk or severity of adverse effects can be increased when Brodalumab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
BudesonideThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Budesonide.Approved
BusulfanThe risk or severity of adverse effects can be increased when Busulfan is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
CanakinumabThe risk or severity of adverse effects can be increased when Canakinumab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
CapecitabineThe risk or severity of adverse effects can be increased when Capecitabine is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
CaplacizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Caplacizumab.Investigational
Capromab pendetideThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Capromab pendetide.Approved
CarbamazepineThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Carbamazepine.Approved, Investigational
CarboplatinThe risk or severity of adverse effects can be increased when Carboplatin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
CarlumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Carlumab.Investigational
CarmustineThe risk or severity of adverse effects can be increased when Carmustine is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Experimental
CatumaxomabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Catumaxomab.Approved, Investigational, Withdrawn
Certolizumab pegolThe risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
ChlorambucilThe risk or severity of adverse effects can be increased when Chlorambucil is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Cisplatin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
CixutumumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cixutumumab.Investigational
CladribineThe risk or severity of adverse effects can be increased when Cladribine is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
ClazakizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Clazakizumab.Investigational
ClenoliximabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Clenoliximab.Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
Coltuximab ravtansineThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Coltuximab ravtansine.Investigational
ConatumumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Conatumumab.Investigational
ConcizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Concizumab.Investigational
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Experimental
CorticotropinThe risk or severity of adverse effects can be increased when Corticotropin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational, Vet Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
CR002The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with CR002.Investigational
CrenezumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Crenezumab.Investigational
CrotedumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Crotedumab.Investigational
CyclophosphamideThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
CyclosporineThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.Approved, Investigational, Vet Approved
CytarabineThe risk or severity of adverse effects can be increased when Cytarabine is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
DacarbazineThe risk or severity of adverse effects can be increased when Dacarbazine is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
DacetuzumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Dacetuzumab.Investigational
DaclizumabThe risk or severity of adverse effects can be increased when Daclizumab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Investigational, Withdrawn
DactinomycinThe risk or severity of adverse effects can be increased when Dactinomycin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
DalotuzumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Dalotuzumab.Investigational
DaratumumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Daratumumab.Approved
DasatinibThe risk or severity of adverse effects can be increased when Dasatinib is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Daunorubicin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
DemcizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Demcizumab.Investigational
DenosumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Denosumab.Approved
DeoxyspergualinThe risk or severity of adverse effects can be increased when Deoxyspergualin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Investigational
DepatuxizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Depatuxizumab.Investigational
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Experimental, Vet Approved
DexamethasoneThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Vet Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
Dimethyl fumarateThe risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
DoxifluridineThe risk or severity of adverse effects can be increased when Doxifluridine is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Investigational
DoxorubicinThe risk or severity of adverse effects can be increased when Doxorubicin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
DulaglutideThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Dulaglutide.Approved, Investigational
DuligotuzumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Duligotuzumab.Investigational
DupilumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Dupilumab.Approved, Investigational
DurvalumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Durvalumab.Approved, Investigational
DusigitumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Dusigitumab.Investigational
EculizumabThe risk or severity of adverse effects can be increased when Eculizumab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
EdrecolomabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Edrecolomab.Experimental, Investigational
EfalizumabThe risk or severity of adverse effects can be increased when Efalizumab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
EldelumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Eldelumab.Investigational
ElotuzumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Elotuzumab.Approved
EmibetuzumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Emibetuzumab.Investigational
EmicizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Emicizumab.Approved, Investigational
EnokizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Enokizumab.Investigational
EpirubicinThe risk or severity of adverse effects can be increased when Epirubicin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
EpratuzumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Epratuzumab.Investigational
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
ErenumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Erenumab.Approved, Investigational
EstramustineThe risk or severity of adverse effects can be increased when Estramustine is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
EtanerceptThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Etanercept.Approved, Investigational
EtaracizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Etaracizumab.Investigational
EtoposideThe risk or severity of adverse effects can be increased when Etoposide is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
EtrolizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Etrolizumab.Investigational
EverolimusThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Everolimus.Approved
EvolocumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Evolocumab.Approved
FarletuzumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Farletuzumab.Investigational
FiclatuzumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ficlatuzumab.Investigational
FigitumumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Figitumumab.Investigational
FingolimodThe risk or severity of adverse effects can be increased when Fingolimod is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
FirategrastThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Firategrast.Investigational
FloxuridineThe risk or severity of adverse effects can be increased when Floxuridine is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
FluasteroneThe risk or severity of adverse effects can be increased when Fluasterone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Investigational
FludarabineThe risk or severity of adverse effects can be increased when Fludarabine is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
FluorouracilThe risk or severity of adverse effects can be increased when Fluorouracil is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
FluticasoneThe risk or severity of adverse effects can be increased when Fluticasone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
Fluticasone propionateThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Fluticasone propionate.Approved
FontolizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Fontolizumab.Investigational
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational, Withdrawn
FremanezumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Fremanezumab.Investigational
FresolimumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Fresolimumab.Investigational
FulranumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Fulranumab.Investigational
GaliximabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Galiximab.Investigational
Gallium nitrateThe risk or severity of adverse effects can be increased when Gallium nitrate is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
GanitumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ganitumab.Investigational
GantenerumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Gantenerumab.Investigational
GemcitabineThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Gemcitabine.Approved
Gemtuzumab ozogamicinThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.Approved, Investigational
GevokizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Gevokizumab.Investigational
GlatiramerThe risk or severity of adverse effects can be increased when Glatiramer Acetate is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
Glembatumumab vedotinThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Glembatumumab vedotin.Investigational
GolimumabThe risk or severity of adverse effects can be increased when Golimumab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
GS 0573The risk or severity of adverse effects can be increased when GS 0573 is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Investigational
GuselkumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Guselkumab.Approved, Investigational
GusperimusThe risk or severity of adverse effects can be increased when Gusperimus is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Investigational
Human C1-esterase inhibitorThe risk or severity of adverse effects can be increased when Human C1-esterase inhibitor is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
Human cytomegalovirus immune globulinThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Human cytomegalovirus immune globulin.Approved
Human Varicella-Zoster Immune GlobulinThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Human Varicella-Zoster Immune Globulin.Approved
HydrocortisoneThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Hydrocortisone.Approved, Vet Approved
Hydrocortisone acetateThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Hydrocortisone acetate.Approved, Vet Approved
Hydrocortisone butyrateThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Hydrocortisone butyrate.Approved, Vet Approved
HydroxyureaThe risk or severity of adverse effects can be increased when Hydroxyurea is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
HypericinThe risk or severity of adverse effects can be increased when Hypericin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Investigational
IbalizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ibalizumab.Approved, Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
IdarubicinThe risk or severity of adverse effects can be increased when Idarubicin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
IdarucizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Idarucizumab.Approved
IdelalisibThe risk or severity of adverse effects can be increased when Idelalisib is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
IfosfamideThe risk or severity of adverse effects can be increased when Ifosfamide is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
IGN311The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with IGN311.Investigational
ImatinibThe risk or severity of adverse effects can be increased when Imatinib is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
IMC-1C11The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with IMC-1C11.Investigational
ImiquimodThe risk or severity of adverse effects can be increased when Imiquimod is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
InclacumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Inclacumab.Investigational
Indium In-111 satumomab pendetideThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Indium In-111 satumomab pendetide.Approved, Withdrawn
InebilizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Inebilizumab.Investigational
InfliximabThe risk or severity of adverse effects can be increased when Infliximab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
Inotuzumab ozogamicinThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Inotuzumab ozogamicin.Approved, Investigational
Interferon alfa-n3The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-n3.Approved, Investigational
IntetumumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Intetumumab.Investigational
IPH 2101The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with IPH 2101.Investigational
IpilimumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ipilimumab.Approved
IratumumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Iratumumab.Investigational
IrinotecanThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Irinotecan.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Investigational
IxekizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ixekizumab.Approved, Investigational
L-PhenylalanineThe risk or severity of adverse effects can be increased when L-Phenylalanine is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational, Nutraceutical
LabetuzumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Labetuzumab.Investigational
LampalizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Lampalizumab.Investigational
LandogrozumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Landogrozumab.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
LenalidomideThe risk or severity of adverse effects can be increased when Lenalidomide is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
LerdelimumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Lerdelimumab.Investigational
LexatumumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Lexatumumab.Investigational
LigelizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ligelizumab.Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Investigational
LomustineThe risk or severity of adverse effects can be increased when Lomustine is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
Lorvotuzumab mertansineThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Lorvotuzumab mertansine.Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
LucatumumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Lucatumumab.Investigational
LumiliximabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Lumiliximab.Investigational
MatuzumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Matuzumab.Investigational
MavrilimumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Mavrilimumab.Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Investigational
MechlorethamineThe risk or severity of adverse effects can be increased when Mechlorethamine is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Vet Approved
MelphalanThe risk or severity of adverse effects can be increased when Melphalan is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
MepolizumabThe risk or severity of adverse effects can be increased when Mepolizumab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
MercaptopurineThe risk or severity of adverse effects can be increased when Mercaptopurine is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
MethimazoleThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Methimazole.Approved
MethotrexateThe risk or severity of adverse effects can be increased when Methotrexate is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
MethylprednisoloneThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Methylprednisolone.Approved, Vet Approved
MilatuzumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Milatuzumab.Investigational
Mirvetuximab SoravtansineThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Mirvetuximab Soravtansine.Investigational
MitomycinThe risk or severity of adverse effects can be increased when Mitomycin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
MitoxantroneThe risk or severity of adverse effects can be increased when Mitoxantrone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Investigational
MogamulizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Mogamulizumab.Approved, Investigational
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Vet Approved
MotavizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Motavizumab.Investigational
MuromonabThe risk or severity of adverse effects can be increased when Muromonab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
MYO-029The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with MYO-029.Investigational
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
Naptumomab EstafenatoxThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Naptumomab Estafenatox.Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Natalizumab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Investigational
NebacumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Nebacumab.Experimental
NecitumumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Necitumumab.Approved, Investigational
NelarabineThe risk or severity of adverse effects can be increased when Nelarabine is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
NilotinibThe risk or severity of adverse effects can be increased when Nilotinib is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
NimotuzumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Nimotuzumab.Investigational
NivolumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Nivolumab.Approved
ObiltoxaximabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Obiltoxaximab.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
OcrelizumabThe therapeutic efficacy of Ocrelizumab can be decreased when used in combination with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
OfatumumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ofatumumab.Approved
OlaratumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Olaratumab.Approved, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Investigational
OlokizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Olokizumab.Investigational
OnartuzumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Onartuzumab.Investigational
OregovomabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Oregovomab.Investigational
OtelixizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Otelixizumab.Investigational
OxaliplatinThe risk or severity of adverse effects can be increased when Oxaliplatin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
OzanezumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ozanezumab.Investigational
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Vet Approved
PalbociclibThe risk or severity of adverse effects can be increased when Palbociclib is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
PalivizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Palivizumab.Approved, Investigational
PanitumumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Panitumumab.Approved, Investigational
PanobinostatThe risk or severity of adverse effects can be increased when Panobinostat is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
PaquinimodThe risk or severity of adverse effects can be increased when Paquinimod is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
PatritumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Patritumab.Investigational
PazopanibThe risk or severity of adverse effects can be increased when Pazopanib is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
PegaspargaseThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pegaspargase.Approved, Investigational
Peginterferon alfa-2aThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Peginterferon alfa-2a.Approved, Investigational
Peginterferon alfa-2bThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Peginterferon alfa-2b.Approved
PembrolizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pembrolizumab.Approved
PemetrexedThe risk or severity of adverse effects can be increased when Pemetrexed is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
PentostatinThe risk or severity of adverse effects can be increased when Pentostatin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
PertuzumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pertuzumab.Approved
PexelizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pexelizumab.Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
PirarubicinThe risk or severity of adverse effects can be increased when Pirarubicin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
Polatuzumab VedotinThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Polatuzumab Vedotin.Investigational
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
PralatrexateThe risk or severity of adverse effects can be increased when Pralatrexate is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
PrednisoloneThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Experimental, Investigational
PRO 140The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with PRO 140.Investigational
PRO-542The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with PRO-542.Investigational
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
R1507The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with R1507.Investigational
RacotumomabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Racotumomab.Investigational
RamucirumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ramucirumab.Approved, Investigational
RanibizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ranibizumab.Approved
RaxibacumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Raxibacumab.Approved
ReslizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Reslizumab.Approved, Investigational
RI 624The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with RI 624.Investigational
RIGScan CR49The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with RIGScan CR49.Investigational
RilonaceptThe risk or severity of adverse effects can be increased when Rilonacept is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
RilotumumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Rilotumumab.Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
RituximabThe risk or severity of adverse effects can be increased when Rituximab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
RobatumumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Robatumumab.Investigational
RomosozumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Romosozumab.Investigational
RontalizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Rontalizumab.Investigational
RuxolitinibThe risk or severity of adverse effects can be increased when Ruxolitinib is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
Sacituzumab govitecanThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Sacituzumab govitecan.Investigational
SarilumabThe risk or severity of infection can be increased when Sarilumab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
SecukinumabThe risk or severity of adverse effects can be increased when Secukinumab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Investigational
SeocalcitolThe risk or severity of adverse effects can be increased when Seocalcitol is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Experimental, Investigational
SeribantumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Seribantumab.Investigational
SibrotuzumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Sibrotuzumab.Investigational
SiltuximabThe risk or severity of adverse effects can be increased when Siltuximab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
SiplizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Siplizumab.Investigational
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
SirukumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Sirukumab.Investigational
SolanezumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Solanezumab.Investigational
SorafenibThe risk or severity of adverse effects can be increased when Sorafenib is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
SteproninThe risk or severity of adverse effects can be increased when Stepronin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
StreptozocinThe risk or severity of adverse effects can be increased when Streptozocin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
SulesomabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Sulesomab.Approved
SulfasalazineThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Sulfasalazine.Approved
SunitinibThe risk or severity of adverse effects can be increased when Sunitinib is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
SYM001The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with SYM001.Investigational
TabalumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tabalumab.Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
TanezumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tanezumab.Investigational
TarextumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tarextumab.Investigational
TB-402The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with TB-402.Investigational
Technetium Tc-99m arcitumomabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Technetium Tc-99m arcitumomab.Approved, Investigational
TemozolomideThe risk or severity of adverse effects can be increased when Temozolomide is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
TeniposideThe risk or severity of adverse effects can be increased when Teniposide is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
TeplizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Teplizumab.Investigational
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
Tetanus Immune GlobulinThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tetanus Immune Globulin.Approved
TetrandrineThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tetrandrine.Experimental
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational, Withdrawn
ThiotepaThe risk or severity of adverse effects can be increased when Thiotepa is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
TildrakizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tildrakizumab.Approved, Investigational
TioguanineThe risk or severity of adverse effects can be increased when Tioguanine is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Withdrawn
TNX-901The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with TNX-901.Investigational
TocilizumabThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
TofacitinibThe risk or severity of adverse effects can be increased when Tofacitinib is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
TopotecanThe risk or severity of adverse effects can be increased when Topotecan is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
TositumomabThe risk or severity of adverse effects can be increased when Tositumomab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
TovetumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tovetumab.Investigational
TrabectedinThe risk or severity of adverse effects can be increased when Trabectedin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
TralokinumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tralokinumab.Investigational
TrastuzumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Trastuzumab.Approved, Investigational
Trastuzumab emtansineThe risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
TRC105The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with TRC105.Investigational
TremelimumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tremelimumab.Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational, Nutraceutical
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Investigational
TrofosfamideThe risk or severity of adverse effects can be increased when Trofosfamide is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
UstekinumabThe risk or severity of adverse effects can be increased when Ustekinumab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
VedolizumabThe risk or severity of adverse effects can be increased when Vedolizumab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
VeltuzumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Veltuzumab.Investigational
VilanterolThe risk or severity of adverse effects can be increased when Vilanterol is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
VinblastineThe risk or severity of adverse effects can be increased when Vinblastine is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
VincristineThe risk or severity of adverse effects can be increased when Vincristine is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
VindesineThe risk or severity of adverse effects can be increased when Vindesine is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
VinorelbineThe risk or severity of adverse effects can be increased when Vinorelbine is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved, Investigational
VisilizumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Visilizumab.Investigational
VoclosporinThe risk or severity of adverse effects can be increased when Voclosporin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Investigational
VolociximabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Volociximab.Investigational
WortmanninThe risk or severity of adverse effects can be increased when Wortmannin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Experimental
XmAb 2513The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with XmAb 2513.Investigational
XTL-001The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with XTL-001.Investigational
ZidovudineThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Zidovudine.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347910742
ATC Codes
J07AM52 — Tetanus toxoid, combinations with tetanus immunoglobulinJ07AM51 — Tetanus toxoid, combinations with diphtheria toxoidJ07AM01 — Tetanus toxoid
AHFS Codes
  • 80:08.00 — Toxoids

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentSubstance Use Disorder (SUD)1
1Active Not RecruitingOtherWhooping Cough1
1Active Not RecruitingTreatmentMalignant Neoplasms of Brain1
1CompletedNot AvailablePertussis1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedPreventionHepatitis C Viral Infection / Human Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1Not Yet RecruitingTreatmentGlioblastomas / Malignant Gliomas / Pediatric Brain Tumor / Pediatric Brain Tumor, Recurrent / Pediatric Glioblastoma Multiforme / Recurrent Medulloblastoma1
1RecruitingTreatmentBrain Cancer / Brain Neoplasms, Recurrent / Cancer of the Brain / Neoplasms, Brain / Primary Brain Neoplasms1
1TerminatedTreatmentGerm Cell Tumors / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm1
1, 2Active Not RecruitingPreventionDiphtheria / Tetanus / Whooping Cough1
2CompletedPreventionAcellular Pertussis / Diphtheria / Haemophilus Influenzae Type B / Haemophilus Influenzae Type b Diseases / Pertussis / Poliomyelitis / Serogroup C Meningococcal Diseases / Tetanus / Viral Hepatitis B1
2CompletedPreventionHealthy Volunteers / Meningococcal Infections1
2CompletedPreventionInfections, Respiratory Syncytial Virus1
2CompletedPreventionInfections, Respiratory Syncytial Virus / Respiratory Synctial Virus Infections1
2CompletedPreventionInfections, Rotavirus / Rotavirus Gastroenteritis1
2CompletedPreventionMeningitis / Meningococcal Infections / Meningococcal Meningitis1
2CompletedPreventionMeningococcal Infections1
2CompletedPreventionShigella Sonnei Infection1
2CompletedTreatmentRelapsing Forms of Multiple Sclerosis1
2Not Yet RecruitingPreventionClostridium Difficile Immunisation / Diphtheria / Diphtheria Immunisation / Pertussis / Tetanus / Tetanus Immunisation1
2RecruitingBasic ScienceAstrocytomas / Gliomas / Oligodendrogliomas1
2RecruitingPreventionPertussis / Whooping Cough1
2SuspendedTreatmentPlasma Cell Myeloma1
2Unknown StatusTreatmentColorectal Cancers1
3CompletedPreventionAcellular Pertussis / Diphtheria / Diphtheria, Tetanus, Pertussis, Poliomyelitis / Tetanus1
3CompletedPreventionAcellular Pertussis / Diphtheria / Diphtheria-Tetanus-acellular Pertussis Vaccines / Pertussis / Tetanus1
3CompletedPreventionAcellular Pertussis / Diphtheria / Haemophilus Influenzae Type B / Poliomyelitis / Tetanus / Viral Hepatitis B1
3CompletedPreventionAcellular Pertussis / Diphtheria / Haemophilus Influenzae Type B / Tetanus1
3CompletedPreventionAcellular Pertussis / Diphtheria / Haemophilus Influenzae Type b Diseases / Pertussis / Tetanus2
3CompletedPreventionAcellular Pertussis / Diphtheria / Pertussis / Poliomyelitis / Tetanus1
3CompletedPreventionAcellular Pertussis / Diphtheria / Pertussis / Tetanus2
3CompletedPreventionAcellular Pertussis / Diphtheria / Poliomyelitis / Tetanus / Viral Hepatitis B1
3CompletedPreventionAcellular Pertussis / Diphtheria / Tetanus3
3CompletedPreventionAcute Otitis Media / Infections, Pneumococcal / Secretory Otitis Media / Tympanic Membrane Perforation1
3CompletedPreventionBacterial Infections / Neisseria Meningitidis / Virus Diseases3
3CompletedPreventionDiphtheria / Haemophilus Influenzae Type B / Pertussis / Poliomyelitis / Tetanus1
3CompletedPreventionHaemophilus Influenzae Type B1
3CompletedPreventionHaemophilus Influenzae Type B / Haemophilus Influenzae Type b Diseases / Meningococcal Serogroup C Diseases / Neisseria Meningitidis1
3CompletedPreventionHepatitis A / Hepatitis A Vaccine1
3CompletedPreventionHerpes Zoster1
3CompletedPreventionInfections, Rotavirus1
3CompletedPreventionInfections, Rotavirus / Meningococcal Meningitis1
3CompletedPreventionInvasive Disease Caused by Neisseria Meningitidis Due to Serogroups A, C, W-135, Y / Meningococcal Infections1
3CompletedPreventionInvasive Pneumococcal Disease (IPD) / Neisseria Meningitidis (Bacterial Meningitis)1
3CompletedPreventionMeningitis / Meningococcal Meningitis1
3CompletedPreventionMeningococcal Disease / Meningococcal Infections1
3CompletedPreventionMeningococcal Infections3
3CompletedPreventionMeningococcal Infections / Meningococcal Serogroup A, C, W-135, Y Diseases1
3CompletedPreventionMeningococcal Meningitis1
3CompletedPreventionNeisseria Meningitidis1
3CompletedPreventionPapillomavirus Infections1
3CompletedPreventionPoliomyelitis1
3CompletedPreventionVaccines, Pneumococcal1
3Not Yet RecruitingPreventionMeningococcal Infections1
4Active Not RecruitingBasic SciencePrevention of Infections With Bordetella Pertussis1
4CompletedPreventionAcellular Pertussis / Diphtheria / Healthy Volunteers / Tetanus1
4CompletedPreventionAcellular Pertussis / Diphtheria / Tetanus2
4CompletedPreventionAcellular Pertussis / Diphtheria / Tetanus / Tetanus and Pertussis1
4CompletedPreventionDiphtheria, Tetanus and Pertussis / Haemophilus Influenzae Serotype b Disease / Meningococcal Disease / Pneumococcal Diseases / Viral Hepatitis B1
4CompletedPreventionDiphtheria-Tetanus-acellular Pertussis Vaccines1
4CompletedPreventionDiphtheria / Meningococcal / Pertussis Diseases / Streptococcal / Tetanus1
4CompletedPreventionDiphtheria / Pertussis / Tetanus2
4CompletedPreventionDiphtheria / Pertussis / Tetanus / Whooping Cough2
4CompletedPreventionDiphtheria / Tetanus1
4CompletedPreventionHepatitis A Virus1
4CompletedTreatmentImmunizations / Meningitis / Pertussis / Preventive Immunization; Meningitis1
4RecruitingPreventionPertussis1
4RecruitingTreatmentSnake Bites1
4TerminatedPreventionAcellular Pertussis / Diphtheria / Hepatitis A / Pertussis / Tetanus1
Not AvailableCompletedNot AvailableAcellular Pertussis / Diphtheria / Tetanus3
Not AvailableCompletedNot AvailableViral Hepatitis B1
Not AvailableCompletedPreventionProlonged Apnea / Prolonged Bradycardia1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableTerminatedNot AvailableCancers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SuspensionIntramuscular
LiquidIntramuscular
Kit; powder, for solutionIntramuscular
Injection, suspensionIntramuscular
InjectionIntramuscular
Injection, suspensionIntramuscular5 [Lf]/.5mL
SuspensionIntramuscular5 lf
LiquidIntramuscular5 lf
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on December 01, 2015 13:04 / Updated on August 15, 2018 09:57